m⁴ Award 2027

create the future of medicine

BAVARIAN BIOTECH CLUSTER DEVELOPMENT

BioM

m⁴ Award

www.m4-award.org

Bayerisches Staatsministerium für Wirtschaft, Landesentwicklung und Energie
www.stmwi.bayern.de

m⁴ Award 2027 – create the future of medicine

It is the vision of the Bavarian biotechnology cluster to establish itself as one of the world's leading locations for precision medicine - the medicine of the future.

m⁴ Award

Bio^{M} – Accelerating Biomedical Innovation

Vision

Bavaria
the place for the medicine of the future

Mission

Bio^{M} creates a unique ecosystem in biotechnology & medicine to accelerate innovation, growth and value creation in Bavaria

Bio^{M} – Biotechnology Cluster Management in a nutshell

- Non-profit cluster management organization funded by the state of Bavaria founded in 1997
- Support for founders, start-ups & SME
- Incubator space (MAxL)
- Attracting investors & industrial partners
- Representing Bavarian biotechnology world-wide
- Events & networking, industry news, company database

Bio[M] for Start-ups – from idea to success

Start-Up Coaching
100+ sessions per year

Mentor Circle
80+ mentors

BioEntrepreneur Bootcamp
>100 teams since 2011

m[4] Award
38 projects, 19 spin-offs

Bio[M] Investors Network
300+ contacts

Munich Accelerator Life Sciences & Medicine – MAxL

Get access to our network, experience, expertise, education, funding and infrastructure!

Munich Accelerator for Life Sciences and Medicine

- Unique co-creation pre-seed & start-up incubator for the future of medicine and planetary health
- Exclusive high-end infrastructure: fully equipped shared labs, co-working and community space
- MAxL support program: incubation, education, events, community
- Teams to get productive exchange with peers, early buyer contact, project development. Access to essential network, resources and financing
- Best of breed pre-seed teams & early startup teams
- Partnerships with pharma, biotech, deeptech, investors, other industry players and strategic partners

MUNICH ACCELERATOR
LIFE SCIENCES & MEDICINE

MAXL by BioM



Current MAxL residents – advancing human and planetary health

ARI-tx

Advanced Respiratory Inhalation Therapeutics (stealth mode)

bindera

AI-Designed Protein Binders (stealth mode)

Connectase

Bioconjugation shaping today's research and tomorrow's therapeutics.

Differential Bio

Virtual Scale-up Platform for Bioprocess Optimization

FLASH Tissue Diagnostics

State-Of-The-Art Lymph Node Analysis

formulaite biotechnology

Fewer experiments. Deeper insights. Better RNA delivery.

ingineeon

Next generation Immuno-therapeutics

Current MAxL residents – advancing human and planetary health

Omics Discoveries

AI-Based RNA-Seq Analysis & Reporting

Oncera

Personalized medicine through AI-based protein binders + tumor-avatars

QUASAR THERAPEUTICS

Transforming therapies for complement-mediated diseases

rnhale

Enabling Inhalable RNA Therapy

SparkSeven Bio

Proprietary antibody discovery technology

ZELLEP

More Science. Less Counting.

Selected MAxL partners – creating value for the ecosystem

Daiichi-Sankyo

Golden Ticket Partner

Johnson&Johnson

Curie.Bio

MERCK

Promega

BIO-RAD

WuXi Biologics
Global Solution Provider

LEYTON
Empower your future

Miltenyi Biotec

WASTELESS BIO
REDUCE REUSE INNOVATE

MathWorks

METTLER TOLEDO

TWIST BIOSCIENCE

Klinikum rechts der Isar
Technische Universität München

LMU LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN

LMU KLINIKUM

CNATM
Cluster for Nucleic Acid Therapeutics Munich

MAxL – your benefits

Low initial investment
Get access to fully equipped state-of-the-art lab and co-working space + lab services

Incubation
Get structured, hands-on support by the MAxL team and our Venture Acceleration Fellows



Community
Interact with the MAxL and IZB community and the extensive pre-seed & startup network of BioM

Events and Network
Enjoy exclusive and public events and connect to the extensive industry network of Bio^{M}

IT & Data
Get access to MAxL IT-, Cloud-, and Data Analysis Infrastructure

Ressources
Get access to attractive offers from MAxL Partners and to and MAxL databases

Education & Training
Profit from our broad trainings & education in bioentrepreneurship, lab tech, financing & business

Funding & Visibility
Profit from our extensive investors network and gain visibility

m⁴ Award – strengthening the Bavarian life science sector with spin-offs

- The m⁴ Award was initiated by BioM and is funded since 2011 by the Bavarian State Ministry for Economic Affairs, Regional Development and Energy (StMWi)
- The StMWi supports measures to intensify and accelerate the positive development of the life sciences in Bavaria to strengthen the competitiveness of the Bavarian economy
- Goal of the m⁴ Award is the accelerated transfer of excellent research results in medical biotechnology into innovative products and technologies and successful exploitation in the form of successful spin-offs / start-ups

m⁴ Award

m⁴ Award – at a glance

2011
initiated by Bio[M]

EUR 500k
funding per project

24
months funding period

8
calls

290+
applications

38
funded projects

19
spin-offs

1
affiliate program:
Medical Valley Award

m⁴ Award

Tubulis – a Munich success story



m⁴ Award – 19 spin-offs since 2011

Bayerisches Staatsministerium für Wirtschaft, Landesentwicklung und Energie

BioM

… and more to come…!

TUBULIS®

Personalized Cancer Immunotherapy
T-CURX

PREOMICS

INVITRIS

smartbax

RevoBITs

granitebio

knowing01

mallia INNOVATIONS

FUSIX BIOTECH
Fighting cancer through fusion

CHERRY biolabs

Toleris

mallia THERAPEUTICS

mallia AESTHETICS

viacure

ROSCUE THERAPEUTICS

TransHeps

Plectonic Biotech

OPSYON

medigene

TRIANTA Immunotherapies

m⁴ Award – 19 spin-offs since 2011

Bayerisches Staatsministerium für Wirtschaft, Landesentwicklung und Energie

BioM

> EUR 3,4 billion capital raised by m⁴ Award start-ups*

*incl. Upfront Payment of EUR 2,7 Mio Exit Tubulis to Gilead; Tubulis potential milestone payments not yet included

m⁴ Award

Write your own success story!

- Teams of scientists at Bavarian universities, university clinics and non-university research institutions are eligible to apply. The receiving institution is the recipient of the grant.

- Research and development projects that can no longer be assigned to basic research are eligible for funding. Only individual projects with spin-off potential are funded, no joint projects.

m⁴ Award

Topics

- innovative **therapeutics** (all modalities, including NCEs, biologicals, ATMPs, vaccines)
- innovative **platform technologies in drug discovery and development** (including approaches based on the application of digital technologies such as artificial intelligence and machine learning)
- innovative **platform technologies in the field of prediction, prognosis, or diagnostics** in biotechnology (including approaches based on the application of digital technologies such as artificial intelligence and machine learning)
- innovative approaches in the field of **digital health** in biotechnology (especially if there is potential for reimbursement by the cost bearers within the framework of the DVG Digital Care Act).



m⁴ Award

Process – next step is stage I

Stage I: Apply with a short project description (5 pages, German or English) via our application portal. The applications are checked formally and thematically in an internal selection meeting and recommendations are made for the creation of a full project outline. You will receive comprehensive advice from Bio^{M}.

Stage II: Apply with a full project outline (15 pages, German) via our application portal. The m^4 Award jury of industry experts and investors assesses the applications, selected projects (10-12) are invited to a jury presentation.

Present your project to the m^4 Award jury. Based on the applications and the presentations, the m^4 Award jury recommends up to 5 promising projects for funding.

The **5 selected winner projects formally apply** via the project management agency Jülich **(PtJ).**

m^4 Award

Application platform Stage I and II

https://m4award2027.alpha-awards.com/auth/login

Herzlich willkommen im Registrierungsportal des m4 Award.

Bitte registrieren Sie sich, um Ihre Bewerbung einzureichen!

Im Anschluss an die Registrierung erhalten Sie eine Registrierungsmail.
Bitte bestätigen Sie diese und füllen Sie das Profil aus.



Important deadlines

Information Event Stage I	October 13, 2026
Deadline short project descriptions (stage I)	**November 30, 2026**
Information event stage II	January 13, 2027
Deadline project outlines (stage II)	**February 22, 2027**
Pitch training for jury presentation	KW 19
Jury presentation	**June 2, 2027**
Feedback to applicants	KW 23
m4 Award ceremony @BayOConnect	July 6 or 7, 2027
Deadline for formal applications of 5 winners (via PTJ: ELAN-FIPS)	July 2027
Funding Confirmations (Zuwendungsbescheide)	October 2027
Project start	**November 2027**

m⁴ Award jury

Marco Winzer
Partner
HighTech-Gründerfonds

Dr. Alexandra Bause
Co-Founder & Managing Director
Apollo Health Ventures

Dr. Holger Reithinger
Senior Advisor
Forbion Capital



Dr. Hella Kohlhoff
CSO
Immunic Therapeutics

Dr. Niels Fertig
CEO
Nanion Technologies

Dr. Regina Hodits
Managing Director Munich
Angelini Ventures

Dr. Elmar Maier
CEO
EM Biotech

Dr. Peter Neubeck
Partner
Kurma Partners

Cédric Barra
Senior Investment
Manager (Life Sciences)
Occident

Dr. Andreas Huber
Senior Investment
Manager
Bayern Kapital

Dr. Johannes Bange
Partner
KHAN



Dr. Marion Jung
Expert Advisor
T-CURX

m⁴ Award

Selection criteria



Spin-off potential and sustainable business model

Motivated and qualified team with aim to form a spin-off

High innovation potential and technical-scientific originality

Significant technical-scientific risk of the R&D project

Unique selling proposition

High probability of spin-off formation after funding period

Positive IP situation

m⁴ Award

Funding amount, funding rate and duration

- A **maximum of €500,000** in funding per project.
- **State universities**: allocation (Zuweisung); full financing or partial financing with **up to 100%** of the eligible expenses within the framework of project funding
- **Non-university research institutions and university clinics**: Partial financing through grants as part of project funding (**up to 90%** of eligible expenses or costs)
- Funding period should not exceed **24 months** (possibly extension by 6 months in the event of unforeseeable delays)
- Start of the funding period: 1st of the month in which personnel expenses are incurred. Expenditures or costs incurred beforehand cannot be taken into account.
- Up to **5 winning teams per competition round** can be supported.

m⁴ Award

Eligible expenses or costs

- **Personnel expenses**; these should outweigh the other project-related expenses
- **Other operating expenses (material, supplies, etc.)** that arise directly from research and development activities
- **Expenditure on contract research**, technical knowledge (but: expenditure on contract research must not exceed personnel expenditure)
- **Expenses for intellectual property rights** acquired directly or under license from third parties
- **Expenditure for consulting** and equivalent services that are used exclusively for the research and development project (external services)
- **Expenditures for instruments and equipment** to the extent and for as long as they are used for the research project.
- **Travel expenses** amounting to up to 2% of personnel expenses according to BayRKG
- **Not eligible:** expenses for rent, other depreciation and administrative overheads.



Stage I: short project description

I. Executive Summary

II. Profile of the future Spin-Off

- Business idea and business model
- Market and competition
- Unique selling propositions (USPs)
- IP situation and IP strategy
- Founder team

III. Outline of the planned R&D project

- Development status and scientific-technical work goals of the project
- Work plan and financial planning
- Project team R&D project

Follow the link to the application platform on www.m4-award.org:

5 pages, Arial 11, spacing 1.5 lines; German or English

Additional material:
CV of project leader

m⁴ Award

Intellectual Property Rights (IP) – contact your TTO!

- In stage II, the responsible technology transfer office or the receiving institution must confirm (Form IP!) that

(a) any existing intellectual property rights or patent applications relevant to the project (insofar as these are held by the receiving institution) - are free of third-party rights, and

(b) both the project-relevant existing intellectual property rights and new inventions/property rights or know-how generated during the funding period are made available to the future spin-off exclusively at standard market conditions in accordance with the funding principles for the m^4 Award.

- Therefore, please contact your technology transfer office and clarify whether they will support your spin-off project!
- Intellectual property rights / patents or proprietary know-how are usually a necessary condition for commercialization in the high-tech sector!

Your contact @BioM

We are happy to support you regarding your application!

Dr. Petra Burgstaller
Co-Lead Venture Creation & MAxL
burgstaller@bio-m.org

+49 (0) 89 899 679 23

Christina Enke-Stolle
Co-Lead Venture Creation & MAxL
enke-stolle@bio-m.org

+49 (0) 89 899 679 26

BAVARIAN BIOTECH CLUSTER DEVELOPMENT

BioM Biotech Cluster Development GmbH
Am Klopferspitz 19a
82152 Martinsried
089-899-679-0

www.m4-award.org

m⁴ Award

Your contact in Regensburg and Würzburg

We are happy to support you regarding your application!

Dr. Ilja Hagen
Geschäftsführer
BioPark Regensburg

i.hagen@biopark-regensburg.de

+49 (0) 941 92 04 6 0

Dr. Gerhard Frank
Projektleiter
IGZ Würzburg

gerhard.frank@igz.wuerzburg.de

+49 (0) 931 78 08 57 11

BioPark Regensburg GmbH
Am BioPark 13
93053 Regensburg

Innovations- und Gründerzentrum Würzburg (IGZ)
Friedrich-Bergius-Ring 15
97076 Würzburg

m⁴ Award

m⁴ Award 2027 – we wish you every success!

www.m4-award.org

Bayerisches Staatsministerium für
Wirtschaft, Landesentwicklung und Energie
www.stmwi.bayern.de